If you hold a Czech commercial health policy as a foreigner, or you have just been assigned to a public insurer through your job, the question is reasonable: does any of this pay for weight-loss treatment?

It is worth answering carefully. The short version is no, but the reason is not what most people assume, and the distinction matters when you are deciding whether to argue with your insurer or simply budget for the treatment.

The short answer

Neither Czech public health insurance nor the commercial policies sold to foreigners will pay for medication prescribed to treat obesity. As of mid-2026, this is a self-pay treatment for everyone in the country, Czech nationals included: an estimated 60,000 to 80,000 people use these medicines, none of it reimbursed (Zdravotnický deník, March 2026, in Czech).

What may be covered is some of the care around it. The general rule is that health services are paid by your insurer when delivered by a provider holding a contract with it (Ministry of Health, in Czech), which is why an appointment at a contracted clinic is treated differently from the medicine itself. Private and online consultations sit outside that network and are paid by the patient. What is covered in any individual case depends on the provider's contract, so ask before you book.

Public health insurance: what VZP and the others actually cover

The Czech public system runs through seven insurers: VZP, the largest, alongside VoZP, ČPZP, OZP, ZP Škoda, ZP MV ČR and RBP. For this question they behave identically, because reimbursement is not decided by the individual insurer. It is set centrally by the drug regulator, SÚKL, in administrative proceedings that determine a medicine's maximum price and the amount and conditions of its reimbursement (SÚKL, in Czech).

For the obesity indication, no such reimbursement currently exists. This is not an insurer-by-insurer lottery, so switching from VZP to another public insurer will not change the answer.

Why you will see one of these medicines on a reimbursement list

Here is where most confusion starts. Search Czech reimbursement databases and you will find that Ozempic does carry reimbursement. People understandably conclude that the system pays for weight-loss medication and that they are being denied something others receive.

That conclusion is wrong, for a regulatory reason. Ozempic is authorised for type 2 diabetes, not obesity, and its reimbursement follows that indication with its own clinical conditions. The eRecept system applies national restrictions to the diabetes packs on top of that: a recorded diagnosis of type 1 or type 2 diabetes, and prescribing limited to internal medicine, diabetology and endocrinology (ePreskripce, in Czech). A medicine reimbursed for a condition you do not have is not coverage you are missing. Reimbursement attaches to an indication, never to a molecule in the abstract.

Commercial policies for foreigners: the PVZP model

This is the part worth reading closely if you are on a residence permit and hold komplexní zdravotní pojištění cizinců, the comprehensive foreigner policy sold by PVZP and comparable insurers.

These policies are marketed as comprehensive and even as having no exclusions. PVZP markets its top Exclusive tier as covering "zcela bez výluk", entirely without exclusions, while describing that tier's scope as comparable ("obdobná") to Czech public health insurance (PVZP, in Czech). Both statements sit on the same page, and read together they explain a lot.

Read them in sequence. The marketing names no exclusion for obesity medication, so nobody has obviously written you out of your contract. But a scope presented as comparable to public health insurance is pegged to a system that reimburses these medicines for nobody, so it is unlikely to reach them, and the reason would be structural rather than a rule applied against you personally.

Note what that argument is, though. It is an inference from a product page, not a reading of your contract. What settles the question are your pojistné podmínky, the general and special terms attached to your policy. Read them, or ask your insurer for the clause that defines scope, before concluding there is no claim worth making.

The same scepticism applies to any broker who implies that a more expensive foreigner policy will unlock these medicines. Within the komplexní pojištění model, a higher premium generally buys higher limits, better service and fewer waiting periods. Ask to see the clause that would cover obesity pharmacotherapy; if there is none, a bigger premium does not create one.

The small silver lining: what your policy may actually pay for

It is not entirely nothing. Two things are worth checking in your own documents.

First, the medical work-up. Before any treatment decision, a doctor may want blood tests, thyroid function, glucose or HbA1c and a review of your current medication. This is diagnostic care rather than obesity pharmacotherapy, so it may fall within your policy's ordinary scope or an extra-benefit rider. Some foreigner policies include preventive-care or check-up benefits that absorb part of this cost.

Second, prevention funds. ZP MV ČR, for example, offers up to 2,000 CZK for adults and up to 4,000 CZK for children who complete long-term obesity treatment supervised by a doctor or nutritional therapist, conditional on a documented reduction of more than 10% of starting weight, and it allows the money to go towards non-reimbursed medicines (ZP MV ČR, in Czech). Amounts and conditions change yearly and differ between insurers, so check your own insurer's current terms rather than assuming this one applies.

Neither turns the treatment into a reimbursed benefit, but both can shave something off the total.

What this means in practice: you pay what Czechs pay

For foreigners, the practical conclusion is more reassuring than it sounds.

Because nothing is reimbursed for anyone, there is no two-tier system here. Pharmacies do not charge foreigners a different price, and no advantage your Czech colleague has is being withheld from you. What the price does depend on is the product, the dose and the individual pharmacy, since retail prices for non-reimbursed medicines are set by each pharmacy rather than fixed nationally, so comparing two or three is worth the effort.

You also do not need a registered Czech GP to begin, worth stating given that more than 554,000 people in Czechia have no registered GP and roughly 65% of them are foreign nationals, a group that spans residents on work and family permits as well as applicants for international protection (expats.cz). For the full cost picture in crowns see our breakdown of what weight-loss treatment costs in Czechia, and if the GP question is your main obstacle, this article covers it.

What could change: the adolescent decision

One part of the picture is genuinely in motion. SÚKL is running an administrative proceeding on reimbursement for obese adolescents, with a decision expected by the end of 2026. The criteria under discussion cover ages 12 to 18 with a BMI above the 97th percentile for age and body weight above 60 kg, always as an addition to dietary change and increased physical activity (Zdravotnický deník, June 2026, in Czech).

That proceeding covers adolescents only, and no equivalent proceeding for adults is under way. In the same reporting, VZP's director Ivan Duškov cautioned that the financial capacity of Czech healthcare has to be weighed in decisions of this kind (Zdravotnický deník, June 2026, in Czech). Treat the adolescent proceeding as what it is: a narrow decision on one age group, not a signal that adult coverage is imminent.

Insurance does not decide whether you are treated

Whatever your policy says, it does not determine whether treatment is appropriate for you. That is a medical judgement. A doctor reviews your history, current medications and goals and decides whether treatment is suitable, which includes deciding it is not and declining to prescribe. Sometimes an in-person examination is required first.

These are prescription medicines with real contraindications and side effects, most commonly gastrointestinal ones such as nausea, vomiting and constipation. Coverage is a budgeting question; suitability is a clinical one, and the two are decided by different people. Check your starting point with the BMI calculator or begin the online assessment.

Frequently asked questions

Does VZP cover weight-loss medication?

No. VZP and the other Czech public insurers do not reimburse medication prescribed for obesity, because reimbursement conditions are set centrally by SÚKL and no such reimbursement exists for this indication as of mid-2026. Switching public insurers will not change this.

Does PVZP insurance cover weight-loss treatment?

Not the medication. PVZP-type comprehensive foreigner policies describe their scope as comparable to Czech public health insurance, which reimburses these medicines for nobody, so a payout is unlikely even though no exclusion names obesity. Your pojistné podmínky are what settle it, so read them or ask your insurer for the clause that defines scope. Diagnostic tests may still fall within your policy's ordinary scope.

Why is Ozempic reimbursed if obesity medication is not covered?

Because it is authorised and reimbursed for type 2 diabetes, not obesity, and reimbursement follows the indication rather than the molecule. The eRecept system applies national restrictions to the diabetes packs: a recorded diagnosis of type 1 or type 2 diabetes, and prescribing limited to internal medicine, diabetology and endocrinology (ePreskripce, in Czech).

Do foreigners pay more than Czechs for weight-loss medication?

No. Nothing is reimbursed for anyone in this indication, and pharmacies do not charge foreigners a different price than Czech patients. Where a difference can appear is in consultation fees, because some private clinics price English-language appointments differently. It is worth asking what a consultation in English costs before you book one.

Does Czech Health Insurance Cover Weight-Loss Medication? (Public, Commercial, and What Foreigners Pay)